Last edition
News about "Relonchem"
Marksans Pharma's UK Arm Relonchem Receives UK MHRA Approval for Mefenamic Acid Tablets
Marksans Pharma announced that its wholly owned UK subsidiary, Relonchem, has received marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for mefenamic acid 250 mg and 500 mg film-coated tablets. The approval further expands Relonchem’s growing footprint in the UK generics market.
Relonchem | 17/11/2025 | By Dineshwori | 173
Relonchem Gets MHRA Nod for Exemestane 25 mg Tablets
Exemestane by Relonchem, a subsidiary of Markans Pharma, is an aromatase inhibitor used in the treatment of hormone-dependent breast cancer in postmenopausal women. The approval marks another milestone in Marksans Pharma’s strategy to expand its oncology portfolio and strengthen its presence in the UK and European markets.
Relonchem | 05/11/2025 | By Dineshwori | 193
Marksans Pharma's UK subsidiary Relonchem Secures MHRA Approval for Clonidine Tablets
Marksans Pharma’s wholly owned UK subsidiary, Relonchem, has received marketing authorisation from the UK Medicines & Healthcare products Regulatory Agency (MHRA) for Clonidine 100 microgram tablets and Clonidine Hydrochloride 25 microgram tablets.
Relonchem | 15/10/2025 | By Dineshwori | 251
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy